Top

Published in:

Open Access 01-01-2020 | Metastasis | Preclinical study

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer

Authors: Abrar I. Aljohani, Michael S. Toss, Sasagu Kurozumi, Chitra Joseph, Mohammed A. Aleskandarany, Islam M. Miligy, Rokaya El Ansari, Nigel P. Mongan, Ian O. Ellis, Andrew R. Green, Emad A. Rakha

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Abstract

Background

Lymphovascular invasion (LVI) is a prerequisite step in breast cancer (BC) metastasis. We have previously identified wild-type isocitrate dehydrogenase 2 (IDH2) as a key putative driver of LVI. Thus, we explored the prognostic significance of IDH2 at transcriptome and protein expression levels in pre-invasive and invasive disease.

Methods

Utlising tissue microarrays from a large well annotated BC cohort including ductal carcinoma in situ and invasive breast cancer (IBC), IDH2 was assessed at the transcriptomic and proteomic level. The associations between clinicopathological factors including LVI status, prognosis and the expression of IDH2 were evaluated.

Results

In pure DCIS and IBC, high IDH2 protein expression was associated with features of aggressiveness including high nuclear grade, larger size, comedo necrosis and hormonal receptor negativity and LVI, higher grade, larger tumour size, high NPI, HER2 positivity, and hormonal receptor negativity, respectively. High expression of IDH2 either in mRNA or in protein levels was associated with poor patient’s outcome in both DCIS and IBC. Multivariate analysis revealed that IDH2 protein expression was an independent risk factor for shorter BC specific-survival.

Conclusion

Further functional studies to decipher the role of IDH2 and its mechanism of action as a driver of BC progression and LVI are warranted.

Available only for authorised users

Rakha EA, Martin S, Lee AHS, Morgan D, Pharoah PDP, Hodi Z, MacMillan D, Ellis IO (2012) The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 118(15):3670–3680. https://doi.org/10.1002/cncr.26711 CrossRefPubMed

Zhang S, Zhang D, Yi S, Gong M, Lu C, Cai Y, Tang X, Zou L (2016) The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget 8(2):2863–2873. https://doi.org/10.18632/oncotarget.13752 CrossRefPubMedCentral

Liu YL, Saraf A, Lee SM, Zhong X, Hibshoosh H, Kalinsky K, Connolly EP (2016) Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 157(3):555–564. https://doi.org/10.1007/s10549-016-3837-5 CrossRefPubMedPubMedCentral

Mohammed RA, Martin SG, Mahmmod AM, Macmillan RD, Green AR, Paish EC, Ellis IO (2011) Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol 223(3):358–365. https://doi.org/10.1002/path.2810 CrossRefPubMed

Aleskandarany M, Sonbul S, Mukherjee A, Rakha E (2015) Molecular mechanisms underlying lymphovascular invasion in invasive breast cancer. Pathobiology. https://doi.org/10.1159/000433583 CrossRefPubMed

Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Group M, Caldas C, Aparicio S, Curtis† C, Shah SP, Caldas C, Aparicio S, Brenton JD, Ellis I, Huntsman D, Pinder S, Purushotham A, Murphy L, Caldas C, Aparicio S, Caldas C, Bardwell H, Chin S-F, Curtis C, Ding Z, Gräf S, Jones L, Liu B, Lynch AG, Papatheodorou I, Sammut SJ, Wishart G, Aparicio S, Chia S, Gelmon K, Huntsman D, McKinney S, Speers C, Turashvili G, Watson P, Ellis I, Blamey R, Green A, Macmillan D, Rakha E, Purushotham A, Gillett C, Grigoriadis A, Pinder S, de Rinaldis E, Tutt A, Murphy L, Parisien M, Troup S, Caldas C, Chin S-F, Chan D, Fielding C, Maia A-T, McGuire S, Osborne M, Sayalero SM, Spiteri I, Hadfield J, Aparicio S, Turashvili G, Bell L, Chow K, Gale N, Huntsman D, Kovalik M, Ng Y, Prentice L, Caldas C, Tavaré S, Curtis C, Dunning MJ, Gräf S, Lynch AG, Rueda OM, Russell R, Samarajiwa S, Speed D, Markowetz F, Yuan Y, Brenton JD, Aparicio S, Shah SP, Bashashati A, Ha G, Haffari G, McKinney S, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale A-L, Brenton JD, Tavaré S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346. https://doi.org/10.1038/nature10983. https://www.nature.com/articles/nature10983#supplementary-information CrossRefPubMedPubMedCentral

Kadota K, Nakai Y, Shimizu K (2008) A weighted average difference method for detecting differentially expressed genes from microarray data. Algorithms Mol Biol 3:8–8. https://doi.org/10.1186/1748-7188-3-8 CrossRefPubMedPubMedCentral

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA (2019) A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. Br J Cancer 120(12):1129–1136. https://doi.org/10.1038/s41416-019-0486-6 CrossRefPubMedPubMedCentral

Gorringe KL, Hunter SM, Pang JM, Opeskin K, Hill P, Rowley SM, Choong DY, Thompson ER, Dobrovic A, Fox SB, Mann GB, Campbell IG (2015) Copy number analysis of ductal carcinoma in situ with and without recurrence. Mod Pathol 28(9):1174–1184. https://doi.org/10.1038/modpathol.2015.75 CrossRefPubMed

10.

Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ (2006) Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 8(5):R61. https://doi.org/10.1186/bcr1613 CrossRefPubMedPubMedCentral

11.

Smolkova K, Jezek P (2012) The role of mitochondrial NADPH-dependent isocitrate dehydrogenase in cancer cells. Int J Cell Biol 2012:273947. https://doi.org/10.1155/2012/273947 CrossRefPubMedPubMedCentral

12.

Teoh ST, Lunt SY (2018) Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond. Wiley Interdiscip Rev Syst Biol Med. https://doi.org/10.1002/wsbm.1406 CrossRefPubMed

13.

Bergaggio E, Piva R (2019) Wild-type IDH enzymes as actionable targets for cancer therapy. Cancers 11(4):563CrossRefPubMedCentral

14.

Lv Q, Xing S, Li Z, Li J, Gong P, Xu X, Chang LE, Jin X, Gao F, Li W, Zhang G, Yang J, Zhang X (2012) Altered expression levels of IDH2 are involved in the development of colon cancer. Exp Ther Med 4(5):801–806. https://doi.org/10.3892/etm.2012.676 CrossRefPubMedPubMedCentral

15.

Raineri S, Mellor J (2018) IDH1: linking metabolism and epigenetics. Front Genet 9:493. https://doi.org/10.3389/fgene.2018.00493 CrossRefPubMedPubMedCentral

16.

Chiang S, Weigelt B, Wen H-C, Pareja F, Raghavendra A, Martelotto LG, Burke KA, Basili T, Li A, Geyer FC, Piscuoglio S, Ng CKY, Jungbluth AA, Balss J, Pusch S, Baker GM, Cole KS, von Deimling A, Batten JM, Marotti JD, Soh H-C, McCalip BL, Serrano J, Lim RS, Siziopikou KP, Lu S, Liu X, Hammour T, Brogi E, Snuderl M, Iafrate AJ, Reis-Filho JS, Schnitt SJ (2016) IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity. Can Res 76(24):7118. https://doi.org/10.1158/0008-5472.CAN-16-0298 CrossRef

17.

Li J, He Y, Tan Z, Lu J, Li L, Song X, Shi F, Xie L, You S, Luo X, Li N, Li Y, Liu X, Tang M, Weng X, Yi W, Fan J, Zhou J, Qiang G, Qiu S, Wu W, Bode AM, Cao Y (2018) Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1alpha in lung cancer. Theranostics 8(15):4050–4061. https://doi.org/10.7150/thno.21524 CrossRefPubMedPubMedCentral

18.

Miligy IM, Gorringe KL, Toss MS, Al-Kawaz AA, Simpson P, Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA (2018) Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. Mod Pathol 31(12):1807–1815. https://doi.org/10.1038/s41379-018-0086-7 CrossRefPubMed

19.

Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, Ellis IO, Green AR, Rakha EA (2018) Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. Mod Pathol 31(11):1675–1682. https://doi.org/10.1038/s41379-018-0092-9 CrossRefPubMed

20.

Rakha EA, Pinder SE, Bartlett JMS, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AHS, Ellis IO, National Coordinating Committee for Breast P (2015) Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol 68(2):93–99. https://doi.org/10.1136/jclinpath-2014-202571 CrossRefPubMed

21.

Rakha EA, Agarwal D, Green AR, Ashankyty I, Ellis IO, Ball G, Alaskandarany MA (2017) Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. Histopathology 70(4):622–631. https://doi.org/10.1111/his.13108 CrossRefPubMed

22.

Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA (2016) MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer 114(8):917–928. https://doi.org/10.1038/bjc.2016.46 CrossRefPubMedPubMedCentral

23.

Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(6):907–922. https://doi.org/10.1043/1543-2165-134.6.907 CrossRefPubMedPubMedCentral

24.

Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350. https://doi.org/10.1002/ijc.21004 CrossRefPubMed

25.

Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR (2011) Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 127(2):407–416. https://doi.org/10.1007/s10549-010-1012-y CrossRefPubMed

26.

El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR (2018) The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Res 20(1):21. https://doi.org/10.1186/s13058-018-0946-6 CrossRefPubMedPubMedCentral

27.

El Ansari R, Craze ML, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR (2018) The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. Br J Cancer 118(8):1115–1122. https://doi.org/10.1038/s41416-018-0038-5 CrossRefPubMedPubMedCentral

28.

Craze ML, Cheung H, Jewa N, Coimbra NDM, Soria D, El-Ansari R, Aleskandarany MA, Wai Cheng K, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR (2017) MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer. Br J Cancer 118:258. https://doi.org/10.1038/bjc.2017.387 CrossRefPubMedPubMedCentral

29.

Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, Pudelko M, Szynglarewicz B, Szelachowska J, Zolnierek A, Kornafel J (2009) The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 29(7):2445–2451PubMed

30.

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519. https://doi.org/10.1016/j.cell.2015.09.033 CrossRefPubMedPubMedCentral

31.

Dawson SJ, Rueda OM, Aparicio S, Caldas C (2013) A new genome-driven integrated classification of breast cancer and its implications. EMBO J 32(5):617–628. https://doi.org/10.1038/emboj.2013.19 CrossRefPubMedPubMedCentral

32.

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA (2019) A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. Br J Cancer. https://doi.org/10.1038/s41416-019-0486-6 CrossRefPubMedPubMedCentral

33.

Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TYT, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambs S (2014) MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Investig 124(1):398–412. https://doi.org/10.1172/JCI71180 CrossRefPubMed

34.

Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GRS, Chandel NS (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107(19):8788–8793. https://doi.org/10.1073/pnas.1003428107 CrossRefPubMedPubMedCentral

35.

Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):331–345. https://doi.org/10.1007/s10549-012-2289-9 CrossRefPubMed

36.

Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA (2000) Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 148(4):779–790. https://doi.org/10.1083/jcb.148.4.779 CrossRefPubMedPubMedCentral

37.

Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, Kawaguchi Y, Fujimoto K, Hosotani R, Imamura M (2004) N-Cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 10(12):4125. https://doi.org/10.1158/1078-0432.CCR-0578-03 CrossRefPubMed

38.

Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, Yang CJ, Yuan L, Ouyang G (2011) Twist2 contributes to breast cancer progression by promoting an epithelial–mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 30:4707. https://doi.org/10.1038/onc.2011.181 CrossRefPubMed

39.

Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A, Sarkar S (2015) EMT and tumor metastasis. Clin Transl Med 4(1):6. https://doi.org/10.1186/s40169-015-0048-3 CrossRefPubMedPubMedCentral

40.

Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21(3):297–308. https://doi.org/10.1016/j.ccr.2012.02.014 CrossRefPubMedPubMedCentral

41.

Cantor JR, Sabatini DM (2012) Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2(10):881–898. https://doi.org/10.1158/2159-8290.Cd-12-0345 CrossRefPubMedPubMedCentral

42.

Laakso M, Loman N, Borg Å, Isola J (2005) Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 18(10):1321–1328. https://doi.org/10.1038/modpathol.3800456 CrossRefPubMed

43.

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan P-H, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS (2010) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24:157. https://doi.org/10.1038/modpathol.2010.200 CrossRefPubMed

44.

Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139(2):539–552. https://doi.org/10.1007/s10549-013-2560-8 CrossRefPubMedPubMedCentral

45.

Hunter KW, Crawford NPS, Alsarraj J (2008) Mechanisms of metastasis. Breast Cancer Res 10(Suppl 1):S2–S2. https://doi.org/10.1186/bcr1988 CrossRefPubMedPubMedCentral

46.

Banin-Hirata BK, de Oliveira CEC, Losi-Guembarovski R, Ozawa PMM, Vitiello GAF, de Almeida FC, Derossi DR, André ND, Watanabe MAE (2018) The prognostic value of regulatory T cells infiltration in HER2-enriched breast cancer microenvironment. Int Rev Immunol 37(3):144–150. https://doi.org/10.1080/08830185.2017.1401620 CrossRefPubMed

47.

Dias K, Dvorkin-Gheva A, Hallett RM, Wu Y, Hassell J, Pond GR, Levine M, Whelan T, Bane AL (2017) Claudin-low breast cancer; clinical & pathological characteristics. PLoS ONE 12(1):e0168669–e0168669. https://doi.org/10.1371/journal.pone.0168669 CrossRefPubMedPubMedCentral

48.

Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F (2014) Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer 13:228. https://doi.org/10.1186/1476-4598-13-228 CrossRefPubMedPubMedCentral

49.

Kordek R, Potemski P, Kusinska R, Pluciennik E, Bednarek A (2010) Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res 29:39. https://doi.org/10.1186/1756-9966-29-39 CrossRefPubMedPubMedCentral

50.

Liao G-S, Hsu H-M, Chu C-H, Hong Z-J, Fu C-Y, Chou Y-C, Golshan M, Dai M-S, Chen T-W, De-Chian C, Tsai W-C, Pan C-W, Hsu K-F, Kao E-N, Hsu Y-C, Chang T-H, Yu J-C (2018) Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. J Med Sci 38(2):54–61. https://doi.org/10.4103/jmedsci.jmedsci_105_17 CrossRef

Title: The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
Authors: Abrar I. Aljohani
Michael S. Toss
Sasagu Kurozumi
Chitra Joseph
Mohammed A. Aleskandarany
Islam M. Miligy
Rokaya El Ansari
Nigel P. Mongan
Ian O. Ellis
Andrew R. Green
Emad A. Rakha
Publication date: 01-01-2020
Publisher: Springer US
Keywords: Metastasis
Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05459-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Long-term prognostic effect of hormone receptor subtype on breast cancer

Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues

Research-based PAM50 signature and long-term breast cancer survival

The intra-tumoural stroma in patients with breast cancer increases with age

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues—author's reply

Keynote webinar | Spotlight on antibody–drug conjugates in cancer